Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The report indicates that the leading spicy snack company is expected to stabilize its noodle products in 2026 while experiencing rapid growth in its konjac new products, driven by scale effects that may lead to better-than-expected performance [2][3] Summary by Relevant Sections Market Outlook - The market perceives insufficient growth momentum for noodle products, with potential ongoing pressure due to weakened industry demand. However, the report suggests that noodle products may stabilize or see slight growth in 2026, while the konjac category is expected to achieve rapid growth through new flavors [2][3] Growth Drivers 1. The konjac industry is projected to grow significantly, with an expected market size exceeding 30 billion yuan by 2025 and a CAGR of 12% over the next five years. The company holds the leading market share and has established strong brand recognition, which provides a competitive advantage. The growth in 2026 will be supported by three new flavors [3] 2. The decline in noodle products is attributed to SKU adjustments, but this impact is expected to diminish in 2026. New flavors and optimized channel displays are anticipated to enhance sales performance [3] 3. The combination of scale effects and cost advantages is expected to improve the company's profitability [3] Financial Forecast and Valuation - The company is projected to achieve revenues of 7.26 billion, 8.59 billion, and 10.14 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 16%, 18%, and 18%. Net profit is expected to reach 1.41 billion, 1.72 billion, and 2.07 billion yuan for the same years, with growth rates of 32%, 23%, and 20% [5][3] - The estimated P/E ratio for 2026 is 16.69, indicating a favorable valuation compared to the industry average of 20.4. The report suggests a target P/E range of 20-25 for the company, corresponding to a market capitalization of 34.5 billion to 43 billion yuan, representing a potential upside of 20%-50% [3]

上 市 公 司 医药生物 报告原因：首次覆盖 研究支持 胡梦婷 A0230524060004 humt@swsresearch.com 买入（首次评级） | 市场数据： | 2026 年 01 月 16 日 | | --- | --- | | 收盘价（港币） | 4.54 | | 恒生中国企业指数 | 9220.81 | | 52 周最高/最低（港币） | 5.76/4.35 | | H 股市值（亿港币） | 285.23 | | 流通 H 股（百万股） | 6,282.51 | | 汇率（港币/人民币） | 0.8988 | 一年内股价与基准指数对比走势： -10% 10% 30% 50% HSCEI 华润医药 资料来源：Bloomberg 相关研究 - 证券分析师 周文远 A0230518110003 zhouwy@swsresearch.com 联系人 胡梦婷 A0230524060004 humt@swsresearch.com 2026 年 01 月 19 日 华润医药 (03320) ——国内第一大 OTC 制造商，品牌势能集聚 华润医药集团有限公司是中国领先的综合医药公司，业务覆盖医药、保健产品 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company, Lin Qingxuan, is positioned as a benchmark for high-end domestic skincare brands, focusing on camellia oil-based products for skin nourishment and anti-aging [3][8]. - The skincare market in China is experiencing significant growth, with the segment for facial oils projected to expand rapidly, driven by consumer preferences for natural ingredients [8][48]. - Lin Qingxuan's revenue and profit are expected to grow substantially, with net profits projected to reach 3.47 billion, 5.77 billion, and 8.20 billion RMB for the years 2025 to 2027, respectively [9][28]. Summary by Sections 1. Camellia Oil as the Foundation for High-End Domestic Skincare Brand - Lin Qingxuan has established a strong market presence with its camellia oil products, achieving over 45 million bottles sold since its launch in 2014 [20]. - The company's ownership structure is stable, with the founder holding approximately 71.34% of the shares, ensuring consistent management [22]. - Revenue is projected to grow from 6.91 billion RMB in 2022 to 12.10 billion RMB in 2024, with a compound annual growth rate (CAGR) of 32.7% [28]. 2. The High-End Skincare Market is Poised for Growth - The Chinese skincare market is expected to grow from 4,619 billion RMB in 2024, with a CAGR of 6.8% [45]. - The facial oil segment is anticipated to grow at a CAGR of 42.8% from 2019 to 2024, significantly outpacing the overall market growth [48]. - The high-end skincare market is projected to reach 2,185 billion RMB by 2029, driven by increasing consumer demand for premium products [61]. 3. Establishing a Strong Brand Matrix Based on Camellia Oil - Lin Qingxuan's core product, the camellia oil essence, has undergone multiple upgrades, maintaining its position as a market leader for over a decade [20]. - The company is expanding its product matrix to include creams, serums, and other skincare products, contributing to a diversified revenue stream [10]. - The company has developed a robust research and development framework focused on enhancing product efficacy and consumer appeal [11]. 4. Building Systematic Organizational Strength and Competitive Barriers - Lin Qingxuan's R&D efforts are centered on camellia oil, enhancing its competitive edge in the anti-aging skincare segment [24]. - The brand leverages both online and offline channels to create a comprehensive consumer experience, with online sales accounting for 65.4% of total revenue in the first half of 2025 [37]. - The company's gross margin has improved from 78% in 2022 to 82.36% in the first half of 2025, reflecting the successful integration of high-margin products [41]. 5. Profit Forecast and Valuation - The company is expected to achieve net profits of 3.47 billion, 5.77 billion, and 8.20 billion RMB from 2025 to 2027, with corresponding price-to-earnings ratios of 31, 18, and 13 [9][28].

证券研究报告：医药生物 | 公司点评报告 股票投资评级 增持|首次覆盖 协议概要：根据协议，英矽智能将有资格获得最高 3200 万美元 的首付款及近期研发里程碑付款，并将依托其自主研发的人工智能技 术平台，筛选并推进符合既定药物研发与科学标准的潜在候选药物。 施维雅将共同承担研发成本，并在成功提名具有前景的候选药物后， 主导后续临床验证、监管沟通，以及相关肿瘤候选药物在全球范围内 的商业化进程。 公司 AI 赋能肿瘤药物研发能力再获认可。 英矽智能在人工智能驱动的肿瘤药物研发方面拥有丰富经验，公 司已建立起覆盖多种癌症适应症的管线。其中，具有潜力成为同类最 佳（best-in-class）疗法的泛 TEAD 抑制剂 ISM6331 以及 MAT2A 抑制 剂 ISM3412，均已启动全球多中心 I 期临床试验。此外，公司还有四 个肿瘤项目已全部或部分对外授权给合作伙伴，相关 I 期临床试验正 在稳步推进中。 公司基本情况 | 最新收盘价（港元） | 55.20 | | | --- | --- | --- | | 总股本/流通股本（亿股）5.57/1.21 | | | | 总市值/流通市值（亿港 | 308/6 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9] Core Views - The management change, with Gao Li taking over as chairman, is expected to lead to a recovery and development for the company. Both Gao Li and Li Shuqing have extensive experience within the China Resources system, which is anticipated to enhance financial control and overall operations [9] - The company is focusing on a dual-engine strategy of water and beverage, continuously enriching its product matrix and launching new products to expand consumer demographics and scenarios [9] - Revenue projections for 2025-2027 are estimated at 11.5 billion, 12.3 billion, and 13.1 billion RMB respectively, with corresponding net profits of 1.1 billion, 1.2 billion, and 1.3 billion RMB [9] Financial Summary - Revenue for 2023 is reported at 13,515 million RMB, with a growth rate of 7.07%. However, a decline of 14.74% is expected in 2025, followed by a recovery in subsequent years [8][11] - The net profit for 2023 is 1,329 million RMB, with a significant growth of 34.30%. A decline of 30.67% is projected for 2025, with a recovery in the following years [8][11] - Earnings per share (EPS) for 2023 is 0.66 RMB, with projections of 0.47 RMB in 2025 and a gradual increase to 0.56 RMB by 2027 [8][11] - The company’s return on equity (ROE) is expected to decline from 19.26% in 2023 to around 9.31% by 2027 [8][11] Financial Ratios - The company’s gross margin is projected to be around 44.66% in 2023, with slight fluctuations in the following years [11] - The debt-to-asset ratio is expected to decrease from 43.29% in 2023 to 30.62% by 2027, indicating improved financial stability [11] - The current ratio is projected to improve from 1.07 in 2023 to 2.23 by 2027, reflecting better liquidity [11]

Investment Rating - The report assigns a "Buy" rating for IFBH, marking its first coverage of the company [1]. Core Insights - IFBH is a leader in the coconut water sector, demonstrating strong profitability and a commitment to a light-asset model that leverages Thai industry resources [8][14]. - The coconut water market in China is rapidly expanding, with a projected growth from USD 1.02 billion in 2019 to USD 10.93 billion by 2024, reflecting a CAGR of 60.8% [8][70]. - The company is actively enhancing its distribution partnerships and product offerings to drive growth, with a focus on both online and offline channels [8][51]. Summary by Sections 1. Company Overview - IFBH was founded in 2013 and has rapidly grown since entering the Chinese market in 2017, becoming a leading player in the coconut water industry [8][14]. - The company operates under a light-asset model, which allows it to maintain high asset turnover and profitability [8][42]. 2. Market Dynamics - The coconut water industry is characterized by its health benefits and growing consumer demand, with significant room for market penetration compared to the U.S. [8][51]. - The market is expected to continue expanding, with a forecasted CAGR of 19.4% from 2024 to 2029 [70]. 3. Growth Strategy - IFBH is focusing on product innovation and expanding its distribution network, including partnerships with major retailers like COFCO and Watsons [8][51]. - The company plans to enhance its market presence through both its flagship brand "if" and the new "Innococo" brand, targeting functional beverage segments [8][29]. 4. Financial Projections - Revenue projections for IFBH indicate growth from USD 187.55 million in 2025 to USD 331.16 million by 2027, with corresponding net profits expected to rise from USD 30.50 million to USD 54.79 million [1]. - The report anticipates a decrease in P/E ratios from 19.29x in 2025 to 10.74x in 2027, indicating improving valuation metrics [1].

Investment Rating - The report maintains a "Buy" rating for the company [3][6] Core Insights - The company plans to acquire Hebei Kangda for a maximum of 450 million RMB, aiming to enhance its performance and strengthen its presence in the northern home care market [1][2] - The acquisition is expected to create synergies between the existing home care business and Hebei Kangda, which has over 30 years of experience in the northern market [3][9] - The company is projected to achieve revenue of 1.996 billion RMB in 2025, 2.397 billion RMB in 2026, and 2.611 billion RMB in 2027, with year-on-year growth rates of 9.7%, 20.1%, and 9.0% respectively [3][5] - The net profit attributable to the parent company is expected to be 223 million RMB in 2025, 268 million RMB in 2026, and 294 million RMB in 2027, with growth rates of 9.8%, 20.2%, and 9.4% respectively [3][5] Financial Summary - The company’s revenue for 2023 is reported at 1,616 million RMB, with a year-on-year growth of 12.0% [5][10] - The net profit for 2023 is 175 million RMB, showing a significant year-on-year increase of 170.4% [5][10] - The projected earnings per share (EPS) for 2025 is 0.17 RMB, increasing to 0.20 RMB in 2026 and 0.22 RMB in 2027 [5][10] - The current market capitalization is approximately 3.25 billion HKD, with a total share count of 1.33 billion shares [6][10]

Investment Rating - The report assigns a "Buy" rating for IFBH, marking its first coverage [1]. Core Insights - IFBH is a leader in the coconut water sector, demonstrating strong profitability and a commitment to a light-asset model that leverages Thai industry resources [8][14]. - The coconut water market in China is rapidly expanding, with a projected growth from USD 1.02 billion in 2019 to USD 10.93 billion by 2024, reflecting a CAGR of 60.8% [8][70]. - The company is actively enhancing its distribution partnerships and product offerings to drive growth, focusing on both innovation and channel expansion [8][51]. Summary by Sections 1. IFBH: Leader in Coconut Water with Strong Profitability - IFBH was founded in 2013 and has rapidly grown in the Chinese market since entering in 2017, supported by a concentrated ownership structure and an efficient management team [8][14]. - The company has adopted a light-asset model, which allows it to maintain high asset turnover and return on equity (ROE) levels [8][42]. - The dual-brand strategy, with flagship brand "if" and sub-brand "Innococo," has contributed to a diversified product matrix, primarily focusing on coconut water [26][29]. 2. Coconut Water: Continuous Expansion and Uncertain Market Structure - The coconut water category is characterized by its natural health benefits and is experiencing significant growth, with the market expected to reach USD 26.52 billion by 2029 [8][70]. - The penetration rate of coconut water in China is still low compared to the U.S., indicating substantial room for growth [8][51]. - The competitive landscape remains fluid, with opportunities for leading brands to educate the market and enhance product innovation [8][51]. 3. Strengthening Distribution Partnerships and Product Development - IFBH is focusing on expanding its distribution network, having signed partnerships with major players like COFCO and Watsons to enhance offline presence [8][51]. - The company is also innovating its product line, including the introduction of electrolyte water under the Innococo brand, to capture growth in the sports drink segment [8][51]. - The light-asset model allows IFBH to mitigate risks associated with raw material price fluctuations while maintaining operational efficiency [8][26]. 4. Profit Forecast and Investment Rating - The report forecasts IFBH's revenue to reach USD 1.88 billion in 2025, USD 2.57 billion in 2026, and USD 3.31 billion in 2027, with corresponding growth rates of 19.0%, 36.9%, and 29.0% [8][1]. - The projected net profit for the same years is USD 0.31 billion, USD 0.42 billion, and USD 0.55 billion, with growth rates of -8.4%, 39.1%, and 29.1% respectively [8][1].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its stock performance [3][6]. Core Insights - The company plans to acquire Hebei Kangda for a maximum of 450 million RMB, aiming to enhance its market presence in the northern home care market and improve competitiveness [1][2]. - The acquisition is expected to increase revenue and profit, leveraging brand synergy and category share to achieve multi-dimensional collaborative effects [2][3]. - The company is positioned as a leader in the home care segment, with a robust multi-brand and multi-category strategy, focusing on both online growth platforms and offline expansion [3]. Financial Projections - Revenue projections for 2025-2027 are estimated at 1,996 million RMB, 2,397 million RMB, and 2,611 million RMB, reflecting year-on-year growth rates of 9.7%, 20.1%, and 9.0% respectively [3][5]. - Net profit estimates for the same period are 223 million RMB, 268 million RMB, and 294 million RMB, with corresponding growth rates of 9.8%, 20.2%, and 9.4% [3][5]. - The current market capitalization corresponds to a PE ratio of 11 times for 2026 [3]. Strategic Acquisition Details - Hebei Kangda has over 30 years of experience in the northern market, specializing in home insecticides and cleaning products, which will enhance the company's resource integration and operational efficiency post-acquisition [9]. - The acquisition is anticipated to solidify the company's market position in household insecticides and cleaning products, thereby reinforcing its leadership in the industry [9]. - Financially, Hebei Kangda reported a revenue of 468 million RMB in 2024, with a net profit of 86 million RMB, indicating strong financial health that will contribute positively to the acquiring company [9].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10][12]. Core Insights - The company has established a comprehensive GBC (Government, Business, Consumer) business model that integrates AI capabilities across the entire medical service cycle, from health risk warning to chronic disease management [4][20]. - The company is expected to achieve revenues of 920 million, 1.18 billion, and 1.47 billion RMB for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 25.6%, 27.6%, and 25.0% [4][10]. Summary by Relevant Sections Company Overview - Founded in 2016, the company leverages the iFlytek Spark Medical Model to provide solutions covering the entire medical service cycle [7][20]. - The ownership structure is concentrated, with iFlytek Group holding 49.4% of shares, ensuring strategic alignment and resource allocation [26][28]. Business Model and Market Position - The company has a significant first-mover advantage, having accumulated extensive data assets through early strategic positioning [8][10]. - The GBC model encompasses a complete medical service loop, addressing challenges in data flow within the healthcare industry [8][10]. Financial Performance - Revenue has shown robust growth, increasing from 373 million RMB in 2021 to an expected 734 million RMB in 2024, with a compound annual growth rate of 25.4% [36]. - The company has improved its net loss from -189 million RMB in 2022 to -133 million RMB in 2024, indicating a positive trend in financial health [37]. Growth Drivers - The company is positioned to benefit from accelerating digitalization and intelligence demands in the healthcare sector, with G and B segments providing stable revenue growth in the short term [10][20]. - The C segment, focusing on patient management services, is anticipated to be a core growth driver in the medium term [10][20]. Technological Advancements - The company has developed the Spark Medical Model, which is the only medical deep reasoning model trained on fully domestic computing power, enhancing its competitive edge [60][61]. - The integration of AI technologies into various healthcare applications is expected to significantly improve operational efficiency and patient outcomes [60][61].